hCTLA-4

• Flow cytometry (FACS) analysis data of humanized CTLA4 mouse

Figure 1. Expression of CTLA4 in the activated spleen lymphocytes of humanized CTLA4 mice is detected by FACS. The spleen lymphocytes of homozygous humanized CTLA4 mice were activated by anti-CD3 and anti-CD28 for 72 hours, and then collected for staining. The expression of humanized CTLA4 was detected by FACS. The results showed that the active expression of humanized CTLA4 can be detected in both activated CD4+ and CD8+ T lymphocytes collected from homozygous humanized CTLA4 mice. (Completed in collaboration with CrownBio).

• In vivo validation in a MC38 tumor-bearing model of humanized CTLA4 mouse

Figure 2. In vivo anti-tumor effect of Ipilimumab, a humanized anti-CTLA4 antibody, in a humanized mouse model of CTLA4

In vivo validation of anti-tumor efficacy in a MC38 tumor-bearing model of humanized CTLA4 mice. Homozygous humanized CTLA4 mice were inoculated with MC38 colon cancer cells. The results showed: Yervoy, a drug targeting human CTLA4, showed a very significant anti-tumor effect (p<0.001), demonstrating that the humanized CTLA4 mice are a good in vivo model for validating the efficacy of antibodies targeting human CTLA4.